Clinically Localized Prostate Cancer: AUA/ASTRO Guideline

No AccessJournal of UrologyJU Forum1 Sep 2022Clinically Localized Prostate Cancer: AUA/ASTRO Guideline James A. Eastham, Stephen A. Boorjian, and Erin Kirkby James A. EasthamJames A. Eastham *Correspondence: Memorial Sloan Kettering Cancer Center, 353 E. 68th St., New York, New York 10065 telephone: 646-422-4322; E-mail Address: [email protected] Memorial Sloan Kettering Cancer Center, New York, New York More articles by this author , Stephen A. BoorjianStephen A. Boorjian Mayo Clinic, Rochester, Minnesota More articles by this author , and Erin KirkbyErin Kirkby American Urological Association, Linthicum, Maryland More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002854AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail REFERENCES 1. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415. Google Scholar 2. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Sci Rep 2019; 9: 17985. Google Scholar 3. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017; 72: 84. Google Scholar 4. Which patients with clinically node-positive prostate cancer should be considered for radical prostatectomy as part of multimodal treatment? The impact of nodal burden on long-term outcomes. Eur Urol 2019; 75: 817. Google Scholar 5. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145. Link, Google Scholar 6. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol 2016; 96: 759. Google Scholar 7. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 2021; 39: 1234. Google Scholar 8. Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. J Urol 2018; 200: 786. Link, Google Scholar 9. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18: 1164. Google Scholar 10. ProstateAJCC Cancer Staging Manual, 8th ed. Chicago, Illinois: Springer International Publishing 2017; chapt 58. Google Scholar Submitted June 27, 2022; accepted June 27, 2022; published July 5, 2022. © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 208Issue 3September 2022Page: 505-507 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information James A. Eastham Memorial Sloan Kettering Cancer Center, New York, New York *Correspondence: Memorial Sloan Kettering Cancer Center, 353 E. 68th St., New York, New York 10065 telephone: 646-422-4322; E-mail Address: [email protected] More articles by this author Stephen A. Boorjian Mayo Clinic, Rochester, Minnesota More articles by this author Erin Kirkby American Urological Association, Linthicum, Maryland More articles by this author Expand All Submitted June 27, 2022; accepted June 27, 2022; published July 5, 2022. Advertisement PDF DownloadLoading ...